Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

149
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
149
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

479
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
479
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

436
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
436
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

1.5K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.5K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

313
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
313

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic Senp2 deletion resolves the angiogenic switch in fibrosis via β-catenin/LECT2.

Biochemical and biophysical research communications·2026
Same author

A dual-aptamer colorimetric sensor based on Cu-MOF@PtPdNPs for the highly sensitive detection of MUC1.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

Frailty, Physical Function Impairment, and Pulmonary Function in Aging Men With and Without HIV from the Multicenter AIDS Cohort Study.

AIDS research and human retroviruses·2026
Same author

A colorimetric/fluorescent/electrochemical tri-modal biosensor based on dual CRISPR/Cas12a system for detection of microRNA.

Analytica chimica acta·2026
Same author

The genetic spectrum of LRRK2 variants in Parkinson's disease: findings from a large Chinese cohort.

NPJ Parkinson's disease·2026
Same author

Association Analysis of HSF1 Variable Number Tandem Repeat Expansion and Coding Variants with Essential Tremor Risk in a Large Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Nov 24, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

Lipid-lowering therapy: Guidelines to precision medicine.

Xin Su1, Ye Cheng1, Dong Chang1

  • 1Department of Cardiology, The Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|December 28, 2020
PubMed
Summary

Dyslipidemia management involves lowering LDL-C with statins, ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. Treatment decisions consider patient profiles for precision cardiovascular disease prevention.

Keywords:
Cardiovascular diseasesClinical precision medicineDyslipidemiaLow-density lipoprotein cholesterolPCSK9 inhibitorsStatins

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.4K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

3

Related Experiment Videos

Last Updated: Nov 24, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.4K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

3

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Dyslipidemia is linked to obesity, insulin resistance, and cardiovascular disease (CVD).
  • LDL-C lowering is crucial for managing metabolic and cardiovascular health.
  • Current treatments include statins, ezetimibe, and bile acid sequestrants.

Purpose of the Study:

  • To review current guidelines for dyslipidemia management.
  • To focus on LDL-C-lowering medications for CVD prevention.
  • To discuss individualized treatment strategies based on LDL-C reduction.

Main Methods:

  • Literature review of dyslipidemia management guidelines.
  • Analysis of LDL-C-lowering medications, including statins and PCSK9 inhibitors.
  • Discussion of treatment approaches for precision medicine.

Main Results:

  • Statins are a primary treatment for lowering LDL-C.
  • PCSK9 inhibitors offer new therapeutic options for dyslipidemia and CVD prevention.
  • Evidence supports individualized treatment based on LDL-C targets.

Conclusions:

  • Effective dyslipidemia management is key to preventing CVD.
  • A range of LDL-C-lowering therapies are available and under investigation.
  • Precision medicine approaches tailor treatment for optimal patient outcomes.